-+ 0.00%
-+ 0.00%
-+ 0.00%

ASCLETIS SUBMITS IND APPLICATION TO THE U.S. FDA FOR ASC30_39 FDC, A POTENTIALLY FIRST-IN-CLASS ORAL SMALL MOLECULE FIXED-DOSE COMBINATION OF GLP-1R AGONIST AND SELECTIVE AMYLIN RECEPTOR AGONIST, FOR THE TREATMENT OF OBESITY

Reuters·11/11/2026 09:10:00

Please log in to view news